Galectin Therapeutics

Update in progress

GALT (NasdaqCM)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease and cancer. Its lead candidate, belapectin (GR-MD-02), is a galectin-3 inhibitor in Phase 2 for MASH with advanced fibrosis and in Phase 2b for MASH with compensated cirrhosis and portal hypertension. The company has a joint venture with SBH Sciences to research oral galectin-3 inhibitors. Formerly Pro-Pharmaceuticals, renamed in 2011. Founded 2000, Norcross, GA.